Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GT 19715

X
Drug Profile

GT 19715

Alternative Names: GT-19715

Latest Information Update: 19 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Suzhou Kintor Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action CRBN protein modulators; Peptide-chain-release factor 3 modulators; Proto oncogene protein c-myc inhibitors; Ubiquitin protein ligase modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 10 Dec 2022 Pharmacodynamics data from a preclinical trial in Acute myeloid leukaemia presented at 64th American Society of Hematology Annual Meeting and Exposition 2022 (ASH-Hem-2022)
  • 15 Nov 2022 Interim pharmacodynamics data from preclinical trial in Acute myeloid leukaemia released by Kintor Pharma
  • 09 Nov 2022 Preclinical trials in Acute myeloid leukaemia in China (unspecified route)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top